Mon, October 15, 2012
Sun, October 14, 2012
Fri, October 12, 2012
Thu, October 11, 2012
Wed, October 10, 2012
Tue, October 9, 2012
Mon, October 8, 2012
Sun, October 7, 2012
Sat, October 6, 2012
Fri, October 5, 2012
Thu, October 4, 2012
Wed, October 3, 2012
Tue, October 2, 2012
Mon, October 1, 2012
Sun, September 30, 2012
Sat, September 29, 2012
Fri, September 28, 2012
[ Fri, Sep 28th 2012 ] - Market Wire
call for signatures
Thu, September 27, 2012
[ Thu, Sep 27th 2012 ] - Market Wire
30 a.m. Eastern
[ Thu, Sep 27th 2012 ] - Market Wire
30pm CT

Verastem to Present at BIO Investor Forum and Participate in Cancer Stem Cell Panel


//health-fitness.news-articles.net/content/2012/ .. m-and-participate-in-cancer-stem-cell-panel.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ ])--Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will present at the BIO Investor Forum on October 9, 2012, at the Palace Hotel in San Francisco, CA.

The company presentation is at 8:30 am PT in the Presidio room and Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research, will participate on a cancer stem cell panel from 10:30-11:25 am PT in the Twin Peaks room.

The panel will bring together scientific experts who are at the forefront of developing novel medicines targeting cancer stem cells. Dr. Pachter will discuss the potential of this approach to create durable clinical responses for patients with cancers that are typically refractory to conventional treatments. Verastem is translating basic science into clinical products based on the seminal publications in Cell and PNAS by Robert Weinberg, Ph.D., Verastem co-founder and chair of the Scientific Advisory Board.

A webcast of the company presentation can be accessed by visiting the investors section of the Companyas website at [ www.verastem.com ]. A replay of the webcast will be archived on the Verastem website for two weeks following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: focal adhesion kinase (FAK), PI3K/mTOR and Wnt. For more information, please visit [ www.verastem.com ].

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Companyas views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.


Publication Contributing Sources